Smith Nicholas Conrad reported option exercise involving 24,056 derivative units of Alto Neuroscience, Inc. at $0.00 for $0 on Sep 30, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
PRESIDENT AND CFO
PRESIDENT AND CFO
Filed Oct 1, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
24,056Employee Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
121,818Direct
Trade date
Sep 30, 2026Option exercise
Filed
Oct 1, 2026, 9:33 PM ET2-day reporting delay
Accession
0002009130-26-000004Code M · Transaction 233630
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 29, 2026Sell110,830$26.58−$2,946,149.56Trade 233624
Sep 30, 2026Sell23,170$25.78−$597,290.16Trade 233626
Sep 30, 2026Sell886$26.87−$23,806.82Trade 233627
Sep 29, 2026Option exercise56,455$0.00$0Trade 233628
Sep 29, 2026Option exercise54,375$0.00$0Trade 233629
Sep 29, 2026Option exercise56,455$2.35$132,669.25Trade 233622
Sep 29, 2026Option exercise54,375$2.35$127,781.25Trade 233623
Sep 30, 2026Option exercise24,056$2.35$56,531.60Trade 233625
9 transaction rows in this filing. Joint filers share the same rows.

ANRO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ANRO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +43%1w ago +47%1d ago +47%
Returns since7d −1.7%30d −8.9%90d180d1y

Footnotes in full

F1: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F2: This price is a weighted average price. These securities were sold in multiple transactions at prices ranging from $26.5513 to $26.5902 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date. F4: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.